Practice Guidelines Developed or Endorsed by C17

Antifungal Prophylaxis:

  • C17 guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell Transplant Recipients (Completed; February 2014)
  • pdf-icon.gif Full Guideline (English Version)
  • A condensed version has been published in Pediatric Blood and Cancer (2014) 61:393-400 
  • Endorsed by ASPHO, COG and POGO

Antithrombotic Therapy and Prevention of Thrombosis:

Chemotherapy-induced Nausea and Vomiting (CINV)

  • The following Pediatric Oncology Group of Ontario (POGO) guidelines related to the management of CINV have been endorsed by C17:
    • Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients (2010)
    • Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients (2012)
    • Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients (2014)
  • Full versions of the POGO CINV guidelines and information regarding related journal publications are available at:  

Fever and Neutropenia:

  • The international guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem cell transplantation (2012) has been endorsed by C17
  • The complete guideline, a condensed version (published in the Journal of Clinical Oncology) and supporting materials are available at:

Platelet Transfusion Thresholds:

  • C17 guideline for platelet transfusion thresholds for pediatric hematology / oncology patients (Updated March 2011) This guideline has been endorsed by the Pediatric Oncology Group of Ontario


C17 Guidelines Currently Being Developed

Guideline for Educational Planning and School Re-entry for Pediatric Oncology Patients (Expected release date: Spring, 2016)

 For further information regarding C17 Guidelines please contact us at